February 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Abdul Mannan: What’s Your Approach When JAK2 Shows Up in Unusual Thrombosis?

Dr Abdul Mannan/Linkedin

Jan 5, 2026, 09:23

Abdul Mannan: What’s Your Approach When JAK2 Shows Up in Unusual Thrombosis?

Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:

”You find JAK2V617F in a patient with splanchnic vein thrombosis.

Counts are normal. The marrow doesn’t show MPN.

Now what?

Here’s the thing: JAK2 positivity in SVT means clonal, persistent risk. It doesn’t disappear just because the blood count looks normal.

Here’s what the evidence tells us:
• JAK2+ SVT behaves as a chronic prothrombotic state, even without overt MPN on counts or marrow
• Budd-Chiari syndrome should get indefinite anticoagulation from the start (target INR 2-3 with LMWH or VKA )
• Portal or mesenteric vein thrombosis with JAK2 positivity usually needs extended or indefinite anticoagulation, tailored to bleeding risk
• Ruxolitinib (Jakavi) is NOT standard for thrombosis prevention alone – it may help if an overt MPN later declares itself, but it doesn’t replace anticoagulation
• Cytoreduction isn’t indicated when counts are truly normal

Here’s what matters for follow-up: some patients do progress to overt MPN over time

. One cohort had 30% declare MPN at a median of 41 months.

So you’re looking at periodic CBCs, iron studies if polycythemia concerns you, and keeping step with hepatology for varices and bleeding risk.

The lesson for clinic: don’t withhold anticoagulation waiting for “diagnostic” marrow features, and don’t reach for ruxolitinib to avoid anticoagulation.

Both are misses.

What’s your approach when JAK2 shows up in unusual thrombosis?”

Abdul Mannan: What’s Your Approach When JAK2 Shows Up in Unusual Thrombosis?